BillionToOne, Inc. (BLLN)

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider Selling

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

BillionToOne SVP Sells 1,416 Shares

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

/C O R R E C T I O N -- BillionToOne/

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Billiontoone, Inc. (NASDAQ:BLLN) Receives $126.71 Average PT from Brokerages

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

Billiontoone Q2 Earnings Call Highlights

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%